Sensex

up-green-arrow

Nifty

up-green-arrow

USDINR

down-red-arrow

GBPINR

down-red-arrow

EURINR

down-red-arrow

Stock Alert

Overall view of all the recent market developments which will help in your investment decisions

 
ONGC, Aurobindo Pharma, BHEL, Sun Pharma in focus
29-May-23 08:36Hrs IST

ONGC: The state-owned oil & exploration company's consolidated net profit tumbled 52.73% to Rs 5,701.46 crore despite of 5.21% rise in revenue to Rs 164,066.72 crore in Q4 FY23 over Q4 FY22.

Aurobindo Pharma: The company's consolidated net profit fell 12.2% to Rs 505.9 crore in Q4 FY23 as against Rs 576.1 crore recorded in Q4 FY22. Revenue from operations stood at Rs 6473 crore in Q4 FY23, up 11.4% from Rs 5809.4 crore posted in Q4 FY22.

BEML: On standalone basis, BEML's net profit rose 17.6% to Rs 158.22 crore in Q4 FY23 as against Rs 134.50 crore posted in Q4 FY22. Revenue from operations declined 17.6% to Rs 1,387.94 crore in the quarter ended 31 March 2023.

BHEL: Bharat Heavy Electricals' (BHEL) consolidated net profit declined 33% to Rs 611 crore in Q4 FY23 as against Rs 912.47 crore reported in Q4 FY22. Revenue from operations rose 2.9% year on year (YoY) to Rs 7,819.37 crore in the quarter ended 31 March 2023.

Indigo Paints: Indigo Paints reported 40.7% jump in net profit to Rs 48.68 crore on 12.9% increase in revenue from operations to Rs 325.47 crore in Q4 FY23 over Q4 FY22.

City Union Bank: The private sector bank's net profit rose 4.3% to Rs 218.04 crore on 13.6% increase in total income to Rs 1,423.09 crore in Q4 FY23 over Q4 FY22.

Karnataka Bank: The private lender's net profit surged 171.4% to Rs 353.75 crore in Q4 FY23 as against Rs 130.35 crore recorded in Q4 FY22. Total income jumped 28.8% to Rs 2,364.54 crore in the quarter ended 31 March 2023.

Chambal Fertilisers & Chemicals: The company's consolidated net profit tumbled 61.4% to Rs 94.10 crore in Q4 FY23 as against Rs 243.57 crore recorded in Q4 FY22. Revenue from operations stood at Rs 3,598.67 crore in Q4 FY23, up 8.8% from Rs 3,307.37crore posted in Q4 FY22.

Sun Pharmaceutical Industries: The company has issued a letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., Israel (Taro) with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the company or its affiliates (For a purchase price of $38 per ordinary share, in cash).

Lupin: The pharma major announced that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise